Ribocure Pharmaceuticals develops RNA-based and oligonucleotide therapeutics targeting rare diseases in cardiovascular, renal, and oncology areas. The company utilizes a vertically integrated research platform to advance first- and best-in-class drug assets, addressing significant unmet medical needs in these therapeutic domains.
Funding
Funding not disclosed
Founders
Product
Problem
Many rare diseases in cardiovascular, renal, and oncology areas lack effective treatments, resulting in significant unmet medical needs. Traditional drug development approaches often struggle to address the complexities of these diseases, leading to limited therapeutic options for patients.
Solution
Ribocure Pharmaceuticals is developing RNA-based and oligonucleotide therapeutics to address rare diseases with significant unmet needs. The company leverages a vertically integrated research platform encompassing R&D, in vitro human cell labs, and a Phase 2 clinical trial unit. Ribocure focuses on creating first- and best-in-class drug assets using innovative oligonucleotide technologies, including siRNA, to target disease-causing genes. Their approach includes target discovery, preclinical development, and clinical trials, with a focus on proof-of-principle and concept trials.
Target Audience
The primary target audience includes patients suffering from rare diseases in cardiovascular, renal, and oncology areas, as well as pharmaceutical companies seeking partnerships for innovative oligonucleotide therapeutics.
Features
- Vertically integrated oligonucleotide research platform for efficient drug development
- Focus on RNA-based therapeutics, including siRNA, for high precision target knockdown
- Specialized Ribocure Clinic for Phase 2 clinical trials with functional imaging capabilities
- RIBO-GalSTAR TM liver targeting technology platform for enhanced drug delivery
- AI-assisted drug discovery through collaboration with Pheiron, leveraging PheironGPS for target identification
- Clinical trial authorization for RBD5044, a siRNA drug targeting APOC3, in patients with mixed dyslipidemia